← Back to all signals
RESEARCH PAPER ANALYSIS

Genomic and transcriptomic determinants of clinical outcomes in patients with AML and DNMT3A mutations.

AI interpretation is pending for this paper.

Open original publication →
PMID40389402
JournalBlood cancer journal
Publication Date2025-05-20
Ingested2026-08-02 12:04 AM
EXECUTIVE SUMMARY

What the AI sees

Not AI summarized yet.

WHY IT MATTERS

Research significance

Pending deeper interpretation.

ABSTRACT

Source abstract

Acute myeloid leukemia (AML) and DNMT3A mutations (DNMT3Amut) are considered to carry intermediate risk under the 2022 European LeukemiaNet (ELN-2022) classification in the absence of other co-mutations or cytogenetic abnormalities. However, this group is highly heterogeneous. In this study, the genomic and transcriptomic features influencing outcomes in DNMT3A-mutated AML were examined in a cohort of 884 patients with AML receiving standard chemotherapy. Stratification by NPM1 and FLT3-ITD status revealed worse survival among patients with NPM1 mutations and wild-type FLT3-ITD (NPM1mut/FLT3-ITDwt) than patients in the ELN-2022 favorable risk group. The other three subgroups (NPM1mut/FLT3-ITDmut, NPM1wt/FLT3-ITDmut, and NPM1wt/FLT3-ITDwt) exhibited worse prognoses than patients in the ELN-2022 intermediate risk group. Additionally, the presence of TET2mut in patients with AML and DNMT3Amut/NPM1mut/FLT3-ITDwt led to reclassification from favorable risk to intermediate risk in the ELN-2022. RNA-sequencing analysis revealed a distinct transcriptomic profile in patients with TET2mut, highlighting the enrichment of leukemic stem cell signatures and dendritic cell migration, with MMP14, CD200, and CT45A5 identified as key differentially expressed genes. In conclusion, co-mutation patterns strongly affected AML outcomes in patients with DNMT3Amut. Patients with TET2mut constituted a unique subgroup within the ELN-2022 favorable DNMT3Amut/NPM1mut/FLT3-ITDwt group, characterized by distinct transcriptomic features and an unfavorable prognosis.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 Congenital Biliary Dilatation With Pre-Existing Diffuse Hepatolithiasis: A Challenging Case. Asian journal of endoscopic surgery 56.4 2 Late-onset familial Mediterranean fever: A case series of missed diagnoses in pleural effusions. Sage open chronic disease 57.8 3 Leadless pacemaker implantation during pregnancy: Quantitative assessment of fetal radiation exposure. Heart rhythm O2 57.2 4 Efficacy Study of Vemurafenib in Children With Recurrent or Progressive BRAFV600E- or BRAFInsT-Mutant Brain Tumors: PNOC002. JCO precision oncology 84.0 5 Hydrocephalus management pathways in pediatric medulloblastoma: a retrospective cohort study. Frontiers in oncology 70.4 6 Adaptation and usability study of the fear of cancer recurrence therapy for parents of survivors of childhood cancer (Parent-FORT). Frontiers in psychology 65.14 7 PTGER4 promoter methylation may serve as an independent prognostic biomarker and is associated with response to hypomethylating agents in pediatric acute myeloid leukemia. Frontiers in pharmacology 76.67 8 Ethical perspectives of fertility preservation through experts' opinions. Frontiers in reproductive health 57.5 9 Computational prioritization of candidate TCDD-associated targets in retinoblastoma using network toxicology and transcriptomic analysis. Frontiers in genetics 50.0 10 Long-term outcomes and prognostic factors in pediatric Wilms tumor: a 47-year single-center experience. The Turkish journal of pediatrics 66.0 11 Recognizing Stuve-Wiedemann syndrome in childhood: clinical insights from 11 patients with founder and novel LIFR variants. The Turkish journal of pediatrics 58.5 12 Spatial and single-cell dissection of medulloblastoma identifies developmental hierarchies and a prognostic PPIA-BSG tumor-immune axis. Journal of translational medicine 58.4 13 Experiences of Parents of Children with Cancer During Their Child's Illness: A Qualitative Interview Study in a Spanish Context. Pediatric reports 60.0 14 Pediatric cancer immunotherapy: The moment has arrived. Molecular therapy. Oncology 54.52 15 Primary Renal Mesenchymal Tumors: A Study from North India, Emphasizing Rare Entities and Molecular Profiles. Journal of kidney cancer and VHL 68.4 16 Long-Term Sequelae in Patients Treated for Recurrent CNS Relapses of Pediatric B-Cell Acute Lymphoblastic Leukemia: 20-Year Follow-Up, Neurological Consequences, and Survivorship Burden-A Case Report and Literature Review. Pediatric reports 62.32 17 Reproductive factors and the expression of stromal markers in benign breast biopsy samples. British journal of cancer 62.0 18 Posterior fossa ependymoma: a comprehensive review of molecular classification, management guidelines, and clinical outcomes (Part I of ependymomas across compartments). Journal of neuro-oncology 71.9 19 Predictive Factors for Malignancy of Thyroid Nodules in Children and Adolescents. World journal of surgery 54.0 20 Sleep quality and disturbances in adolescents and young adults with cancer compared to a healthy comparison group: results of the AYA-LE study. Journal of cancer research and clinical oncology 62.5 21 Exploring young adult cancer survivors' perspectives on generative AI chatbots for symptom support. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 61.9 22 A survey on the institutional practices of the use of isavuconazole in onco-hematological children, on behalf of the Infectious Working Group of AIEOP. European journal of pediatrics 68.7 23 Predicting late-onset hydrocephalus in pediatric medulloblastoma: from static anatomy to dynamic biological assessment. Neurosurgical review 62.5 24 Health risk assessment of heavy metals exposure in soil at Rafin Gora artisanal gold mining area, Nigeria. Environmental science and pollution research international 57.5 25 Evidence-Informed Multidisciplinary Consensus Guidance for the Psychosocial Care of Adolescents With High-Risk Cancer: Recommendations From the Italian Association of Pediatric Hematology and Oncology. Pediatric blood & cancer 59.9 26 Bone Marrow and Lymph Node Involvement in Newly Diagnosed Pediatric Rhabdomyosarcoma: Can 18F-FDG PET/CT Replace Bone Marrow and Lymph Node Biopsies? Analysis of the "Paris Kids Cancer" Cohort. Pediatric blood & cancer 63.9 27 Retrospective Analysis of Donor Lymphocyte Infusions in Pediatric Patients With Mixed Chimerism After Hematopoietic Stem Cell Transplantation. Pediatric blood & cancer 69.7 28 Temporal Trends and Drivers of Cervical Cancer Overscreening Among Adolescent Girls and Young Women, 2011-2023. The Journal of adolescent health : official publication of the Society for Adolescent Medicine 64.5 29 Ventricular Arterial Coupling as a Marker of Early Cardiotoxicity in Survivors of Childhood Cancer. Pediatric cardiology 68.92 30 A phase 2 pharmacokinetic and pharmacodynamic dose-finding study of oral NEPA for chemotherapy-induced nausea and vomiting in pediatric patients with cancer. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 83.96 31 Acceptance and perceived efficacy of intraoral versus extraoral photobiomodulation for oral mucositis prevention in pediatric patients. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 62.8 32 Impact of Tramadol Administration on Stomach and Duodenum of Male Rats: Histological Examinations, DNA and Biochemical Analyses. Cell biochemistry and biophysics 60.6
PATIENT-FRIENDLY SUMMARY

Genomic and transcriptomic determinants of clinical outcomes in patients with AML and DNMT3A mutations.

For education only—not personal medical advice.

Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic